Letters to the Editor

Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Haematologica Early view May 23, 2024 https://doi.org/10.3324/haematol.2023.284950